RankingsPricing
  1. US-listed companies
  2. REGENERON PHARMACEUTICALS, INC.
  3. Financials
  4. Cash from operations

REGENERON PHARMACEUTICALS, INC.REGN

Market cap
$81.6B
P/E ratio
SummaryFinancials
Period EndCash from operations (Million USD)YoY (%)
Dec 31, 20244,421-3.78%
Dec 31, 20234,594-8.39%
Dec 31, 20225,015-29.18%
Dec 31, 20217,081+170.47%
Dec 31, 20202,618+7.74%
Dec 31, 20192,430+10.70%
Dec 31, 20182,195+67.94%
Dec 31, 20171,307-11.29%
Dec 31, 20161,473+10.72%
Dec 31, 20151,331+79.07%
Dec 31, 2014743+27.33%
Dec 31, 2013584-882.21%
Dec 31, 2012-75-47.34%
Dec 31, 2011-142-247.06%
Dec 31, 201096

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)